Navigation Links
Future Therapeutic Drug Monitoring Market: US, Europe, Japan
Date:12/7/2011

6; Vital Diagnostics ATAC 8000

° Vital Diagnostics Envoy 500

C. Major In Vitro Diagnostic Technologies

And Their Potential Applications

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassays (RIA)

c. Enzyme Immunoassays (EIA)

° Overview

° ELISA

° EMIT

° Immunofiltration

° Dot Immunobinding Assays

° Capillary ImmunoassaysTable of Contents (Continued)

° Particle-Membrane Capture Immunoassays

° Enzyme Amplification

° CEDIA

° Electrochemical Immunoassays

d. Fluorescent Immunoassays

° Fluorescence Polarization

° Time-Resolved Pulse Fluorescence

e. Luminescence

° Chemiluminescence

° Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

h. Affinity Chromatography Immunoassays

i. Liposome Flow-Injection Immunoassays

3. IT and Automation

4. Dry Chemistry

5. Biosensors

6. Robotics

7. Chemometrics

8. Molecular Diagnostics

a. Sample Preparation

b. Hybridization

c. Separation

d. Detection/Measurement

Test Formats

a. Filter Hybridization

b. Southern Blot

c. Northern Blot

d. In Situ Hybridization

e. Others

Labeling Techniques

Amplification Methods

? Polymerase Chain Reaction

- Temperature Cyclers

- PCR Variations

* Immuno-PCR

* QC-PCR.

* DAP-PCR

? Strand Displacement Activation

? TMA

? Ligase Chain Reaction

? Branched DNATable of Contents (Continued)

- Hybridization Protection Assay

? Nucleic-Acid Sequence-Based Amplification

? Self-Sustained Sequence Replicase

? Others

- Ampliprobe

- CAR

- CAS

- CPT

- D
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Futuremed and Cardinal Health Canada Inc. Report on Developments in Competition Bureau Review of the Proposed Acquisition
2. Cardinal Health Canada Inc. Mails Offer and Take-Over Bid Circular to Futuremed Shareholders
3. Current Trends and Future Directions in Physician E-Sampling Programs for the Pharmaceutical Industry
4. International Experts Outline Public Health Initiatives for Future Dengue Vaccine Introduction and Control of Dengue Fever
5. Diplomat Specialty Pharmacy Recipient of MichBio Good to Great Award; Also Featured in Pure Michigan Video Exemplifying Flints Resurgence and Michigans Future
6. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
7. Philips Teams up With Integrated Oncology Network, Reinforcing Its Commitment to the Future of Cancer Care
8. CVS Caremark Partners With Hispanic Heritage Foundation to Identify and Inspire Future Latino Health Care Leaders
9. Spot Helps Redefine the Pediatric Office of the Future
10. Contraceptives Market to 2017 - Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future
11. The Future of European Pharmaceutical Distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 Cure SMA recently announced a ... Biomedical Research (CALIBR). This funding is an extension of a ... a $700,000 Cure SMA grant to Dr. Peter G. ... "Optimization of Small Molecules that Increase SMN2 Levels ... motor neuron (SMN) protein is critical to the function of ...
(Date:3/2/2015)...  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... for the fiscal first quarter 2015 after the market ... The Company will also host a conference call for ... Central Time (10:00 a.m. Eastern Time). Investors may access ...
(Date:3/2/2015)... 2015 Amgen (NASDAQ: AMGN ) ... data evaluating Repatha TM (evolocumab), an investigational cholesterol-lowering ... for chronic heart failure, at the upcoming American College ... being held March 14-16 in San Diego ... monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 ...
Breaking Medicine Technology:Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 4Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 5Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 6Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 7Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 8Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 9Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 10Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 11
... in Poor Risk Frontline Elderly AML and in Combination with Cytarabine ... Call Scheduled for Tuesday, December 9 at 11:00 am ET to ... , SAN FRANCISCO , Dec. 7 ... the presentation of new data from two ongoing clinical trials demonstrating ...
... carisbamate, an,investigational compound recently filed with the FDA for ... 16 years of age and,older, was presented today during ... American Epilepsy Society. , ... efficacy, safety and tolerability of carisbamate as an,adjunctive treatment ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 2Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 3Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 4Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 5
(Date:3/2/2015)... 02, 2015 Formetco today announced the ... The FTX uses state-of-the-art technology to deliver an ... and owner satisfaction. An item of particular value, ... Formetco 10 year LED Brightness Warranty. , Why the ... a superior billboard among any other billboard product in ...
(Date:3/2/2015)... 02, 2015 Calvary Hospital recently ... Brooklyn Satellite in Lutheran Medical Center, with the ... must demonstrate excellence through clinical expertise as well ... to go above and beyond to make a ... patients and their families. Award recipients are chosen ...
(Date:3/2/2015)... Getting customers to discover a whole ... this March as the 31st annual Frozen Food Month ... Frozen & Refrigerated Foods Association (NFRA) to stimulate the ... than 20 delicious frozen selections and is thrilled to ... frozen options are crafted with simple ingredients, no preservatives ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Today ... Luis Obispo), in partnership with the California Healthcare ... Disorders (NORD), presented an Assembly resolution recognizing Feb. ... families and healthcare professionals caring for millions of ... is a nonprofit, public policy research organization, representing ...
(Date:3/2/2015)... York, New York (PRWEB) March 02, 2015 ... behalf of women who were allegedly harmed by the ... state and federal courts around the U.S., according to ... U.S. District Court, Eastern District of California on February ... a case pending in that jurisdiction may pursue her ...
Breaking Medicine News(10 mins):Health News:Formetco Launches Innovative LED Billboard System 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Take a Fresh Look at Frozen with Ian’s 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 4
... Cost Saving Benefit Faces Eventual Elimination Without Relief ... support of President Obama,s pledge not to raise taxes on ... -- outside of the normal legislative process -- adopting provisions ... restrict the use of flexible spending accounts (FSAs) in order ...
... Oct. 14 New Enterprise Associates, Inc. (NEA), a leading ... has been promoted to General Partner. Dr. Viswanathan, who joined ... equity information technology investments, as well as the firm,s activities ... Principal. Dr. Torti joined NEA in 2007 and is focused ...
... Networks , the nation,s leading provider of physician office-based ... consumer purchase behavior, not just purchase intent, for OTC ... revenue and justify investments designed to capture market share, ... health messages to purchase volume. To address this need ...
... aged 70-79, the apparent association between light-to-moderate alcohol consumption ... not hold up after adjustments were made for characteristics ... education, and income. The authors of the ... American Geriatrics Society , say this suggests that life-style ...
... SAN DIEGO, Oct. 14 Cardium Therapeutics (NYSE Amex: ... Matrix Phase 2b clinical trial of Excellarate(TM) for the ... ulcers based on the Company,s Gene Activated Matrix (GAM) ... the Excellarate product candidate (GAM501, which is a combination ...
... Continuing its efforts to educate, inform, and empower ... patient-focused organization, is hosting its 25-minute live call-in show, ... Monday, October 19, 2009 at 6:00 PM on Channel ... frank discussion regarding Retail Health Clinics with Erin Buckley, ...
Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 2Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 3Health News:'Beneficial' effects of alcohol? 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14Health News:Retail Health Clinics - The Real Story 2
... 4420 Colloid Osmometer. Rapid measurement of ... prediction of edema onset in clinical ... sample and reference chambers to simulate ... membrane in the establishment of osmotic ...
... Automated Cortisol assay with flexible ... workflow, Excellent correlation and agreement ... confidence,in assay performance, Standardized to ... Panels delivers assurance in,accuracy of ...
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
Medicine Products: